Braidwell LP Sells 167,458 Shares of BioAge Labs, Inc. $BIOA

Braidwell LP decreased its holdings in shares of BioAge Labs, Inc. (NASDAQ:BIOA) by 13.9% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,033,129 shares of the company’s stock after selling 167,458 shares during the period. Braidwell LP’s holdings in BioAge Labs were worth $25,322,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Legal & General Group Plc purchased a new stake in shares of BioAge Labs in the 2nd quarter worth approximately $84,000. CWM LLC increased its holdings in BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after buying an additional 1,053 shares during the period. Russell Investments Group Ltd. bought a new position in BioAge Labs in the third quarter worth approximately $27,000. State of Wyoming bought a new position in BioAge Labs in the second quarter worth approximately $154,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in BioAge Labs during the second quarter worth $234,000.

BioAge Labs Stock Up 2.2%

NASDAQ:BIOA opened at $9.73 on Thursday. The stock has a market capitalization of $446.61 million, a price-to-earnings ratio of -4.09 and a beta of 0.94. BioAge Labs, Inc. has a 52 week low of $4.55 and a 52 week high of $25.95. The firm has a 50 day moving average of $17.05 and a 200 day moving average of $17.95.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.07. The business had revenue of $2.45 million for the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. As a group, analysts expect that BioAge Labs, Inc. will post -2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BIOA. BTIG Research reiterated a “buy” rating and issued a $40.00 price target on shares of BioAge Labs in a report on Monday, August 3rd. Jefferies Financial Group set a $21.00 price objective on BioAge Labs in a research note on Friday, July 31st. Roth Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of BioAge Labs in a research report on Friday, July 31st. Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Finally, Needham & Company LLC reduced their target price on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a report on Friday, July 31st. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, BioAge Labs presently has an average rating of “Moderate Buy” and a consensus price target of $36.57.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.